Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Novo Nordisk Files Lawsuit Against Eli Lilly Over GLP-1 Drug Advertisements

    Novo Nordisk has announced that it has filed a lawsuit against Eli Lilly and Company in the United States, alleging that Lilly's advertising campaigns for its GLP-1 medicines are misleading and do not present complete scientific information.

  • US FDA Issues Warning Letter to Alembic Pharmaceuticals Over Clinical Study Consent Process
    The US Food and Drug Administration (FDA) has issued a Warning Letter to Alembic Pharmaceuticals Ltd. after identifying deficiencies during an inspection of the company's bioequivalence research facility in Vadodara, Gujarat. The inspection was conducted between March 3 and March 7, 2025, as part of the FDA's Bioresearch Monitoring Program.
  • Sanofi Publicly Reprimanded by UK Pharma Watchdog After Pfizer Complaint

    Global pharmaceutical company Sanofi has received a Public Reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) after a complaint was filed by Pfizer.

    The PMCPA investigated the case (CASE/0689/08/25) and found that Sanofi had breached several rules of the 2024 ABPI Code of Practice, which sets standards for how pharmaceutical companies should promote their medicines in the UK.

  • ICMR Transfers Three Indigenous Biomedical Technologies to Indian Industry for Cancer and Vaccine Development

    The Indian Council of Medical Research (ICMR) has transferred three indigenous healthcare technologies to leading Indian pharmaceutical and vaccine manufacturers for further development, manufacturing, and commercialization. The initiative is aimed at accelerating affordable healthcare solutions while strengthening the country's self-reliance in medical innovation.

  • USFDA Issues One Observation After Routine cGMP Inspection at Cipla's InvaGen Facility in New York

    Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.

    The inspection was carried out from July 13 to July 17, 2026 (EDT) as part of the USFDA's routine regulatory oversight of pharmaceutical manufacturing facilities.

  • One in Four High-Risk Families Unaware of Type 1 Diabetes Risk, Survey Reveals

    A new survey has uncovered significant knowledge gaps among families with a history of type 1 diabetes (T1D), highlighting misconceptions that may delay early screening and diagnosis despite their increased risk of developing the disease.

    The survey, titled "The Family Factor: A T1D Risk Awareness Survey," was conducted by global diabetes nonprofit Beyond Type 1 and commissioned by Sanofi. It focused on adults and caregivers with a first-degree family member living with type 1 diabetes.

  • New approach to the development of non-opioid painkillers

    An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an animal model. Crucially, its effect takes hold immediately after subcutaneous injection, whereas previously known cone snail peptides must be administered directly into the cerebrospinal fluid.

  • Scientists Uncover Biomedical Promise of Rare Atom-Containing Natural Products in Comprehensive

    Modern research on secondary metabolites from microbes, plants, and marine organisms has revealed a remarkable diversity of chemical structures and bioactivities with broad applications in biotechnology, agriculture, and medicine. Most natural products are composed of primary biogenic elements such as carbon, hydrogen, nitrogen, and oxygen.  

  • Alembic Partner NATCO Gets USFDA Tentative Approval Olaparib Tablets

    Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

    Alembic Pharmaceuticals Limited (Alembic) today announced that its Partner NATCO Pharma Limited (NATCO) has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olaparib Tablets, 100 mg and 150 mg. 

  • India Approves First Dengue Vaccine : DCGI Clears Takeda's QDENGA for People Aged 4-60 Years

    In a landmark development for dengue prevention, the Drug Controller General of India (DCGI) has granted market authorization to Takeda Biopharmaceuticals India's QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]), making it the first dengue vaccine approved in India. The vaccine is approved for the prevention of dengue in individuals 4 to 60 years of age and can be administered regardless of prior dengue infection, eliminating the need for pre-vaccination screening.

Subscribe to Pharma News